Frontlight ResearchEarly access
Taking people in PolandPhase 4
Cytisine versus nicotine patches for quitting smoking in people with kidney disease
Compares long-term cytisine with nicotine replacement in adults with kidney disease who smoke.
Key facts
- Who runs it
- Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
- Where
- Warsaw, PolandSee the site
- Trial code
- Registry title
- Cytisine in prolonged dosage versus Nicotine Replacement Therapy in nicotine-dependent patients with Chronic Kidney Disease - single-center, randomized, non-inferiority clinical trial.
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 292 people, planned
- Started
- 30 Oct 2025
- Expected to end
- 28 Apr 2028
- Type of study
- Interventional
- Record updated
- 29 July 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who smoke every day and want to quit, and who have chronic kidney disease of at least stage 3.
- Age
- From 18 to under 65 years.
- Sex
- Women and men can join.
- Disease stage
- Chronic kidney disease of at least stage 3 (eGFR MDRD below 60 ml/min and above 15 ml/min for at least 3 months).
- Earlier treatment
- Must not have taken other smoking cessation medicines (bupropion, varenicline, nortriptyline) in the last 4 weeks. Must not have been in another drug trial in the last 4 weeks.
Main reasons for not taking part
- Allergy to cytisine, its other ingredients or nicotine products
- Liver damage signs (AST/ALT more than 2x above normal)
- Uncontrolled high blood pressure above 160/100 mm Hg
- Heart attack, stroke or heart failure needing hospital care in the last 3 months
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patient (woman or man) who wants to participate in the study and is able to give a written informed consent
- Age over or equal to 18 and under 65
- Current daily cigarette smoker - a person who smokes tobacco products every day or almost every day for at least 3 months
- Motivation and willingness to try to quit smoking with medication, assessed in conversation with the patient
- Chronic kidney disease at least stage 3, defined as impaired glomerular filtration eGFR MDRD < 60 ml/min and > 15 ml/min persisting for at least 3 months preceding qualification for the study
- Women of reproductive age: a) exclusion of pregnancy by testing the concentration of beta HCG in the urine; b) consent to use a highly effective method of contraception during treatment
- Telephone access
Who cannot take part
- Treatment in the last 4 weeks with other smoking cessation medications (bupropion, varenicline, nortriptyline)
- Participation in another clinical trial of the drug in the 4 weeks before randomization
- Recent history of myocardial infarction, stroke, heart failure requiring hospitalization (within 3 months before randomization)
- Hypersensitivity to cytisine or any of the excipients or nicotine preparations
- Currently uncontrolled hypertension above 160/100 mm Hg
- Documented diagnosis of: schizophrenia, bipolar psychoaffective disorder, epilepsy, symptoms of moderate to severe depression
- Biochemical features of liver damage (AST/ALT > 2x above normal)
- Pheochromocytoma of the adrenal glands
- Current other addiction (alcohol, other psychoactive substances)
- Pregnancy or breastfeeding
- Male or female persons of childbearing potential who do not consent to the use of adequate birth control methods during the study treatment period
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Poland
- Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu MedycznegoWarsaw, PolandTaking people
About the trial
What the trial wants to find out
Assessment and comparison of the efficacy of treatment in study arm and control group in 6 months.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Cytisine in prolonged dosage versus Nicotine Replacement Therapy in nicotine-dependent patients with Chronic Kidney Disease - single-center, randomized, non-inferiority clinical trial.
- Plain-language title
- Cytisine versus nicotine patches for quitting smoking in people with kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2023-509235-39-00, who can take part
- Record updated
- 29 July 2024